Sign In
Buy BLCO
$14.87
-0.110 (-0.734%)
At Close: Jun 03, 2026
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
07:15am, Monday, 30'th Mar 2026
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter
Bausch + Lomb Corporation (NYSE:BLCO) Short Interest Up 50.7% in March
05:32am, Monday, 30'th Mar 2026
Bausch + Lomb Corporation (NYSE: BLCO - Get Free Report) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 4,006,617 shares, a growth of
Bausch + Lomb Corporation (NYSE:BLCO) Short Interest Up 50.7% in March
05:32am, Monday, 30'th Mar 2026
Bausch + Lomb Corporation (NYSE: BLCO - Get Free Report) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 4,006,617 shares, a growth of
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story
07:24pm, Tuesday, 24'th Mar 2026
Alfonso Eduardo acquired 4,300 common shares on March 2, 2026, at around $17.90 per share, for a total transaction value of ~$77,000. Bausch + Lomb, matched his purchase with restricted stock units, r
Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript
10:33pm, Monday, 23'rd Mar 2026
Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma
07:00am, Monday, 23'rd Mar 2026
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced positive 24-mo
Bausch + Lomb Corporation Investigated by the Portnoy Law Firm
09:00am, Friday, 13'th Mar 2026
LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bausch + Lomb Corporation , (“ BLCO " or the "Company") ( NYSE : BLCO ) investors that the firm has initiated an investig
Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position
01:26pm, Thursday, 12'th Mar 2026
Caspian Capital increased its Bausch + Lomb Corporation stake by 1,349,043 shares in the fourth quarter; the estimated trade value was $21.39 million based on quarterly average prices. Meanwhile, the
Bausch + Lomb Launches R&D “Teach-in” Webinar Series
07:15am, Monday, 09'th Mar 2026
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first even
Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®
07:00am, Tuesday, 24'th Feb 2026
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced today that Ophthalmo
Bausch + Lomb Q4 Earnings Review: Still A Buy, With Some Caveats
02:54pm, Thursday, 19'th Feb 2026
Bausch + Lomb delivered 7% constant currency Q4 revenue growth and 27% adjusted EBITDA growth, reinforcing strong operating leverage. I maintain my Buy rating on BLCO, citing robust revenue momentum,
Bausch + Lomb (BLCO) Upgraded to Buy: Here's What You Should Know
01:01pm, Thursday, 19'th Feb 2026
Bausch + Lomb (BLCO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bausch + Lomb (NYSE:BLCO) Shares Gap Down Following Weak Earnings
01:59am, Thursday, 19'th Feb 2026
Bausch + Lomb Corporation (NYSE: BLCO - Get Free Report) shares gapped down prior to trading on Wednesday following a dissappointing earnings announcement. The stock had previously closed at $17.73, b
Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript
12:55pm, Wednesday, 18'th Feb 2026
Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript
Bausch + Lomb (BLCO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
10:31am, Wednesday, 18'th Feb 2026
The headline numbers for Bausch + Lomb (BLCO) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street
